explore -WSS

explore

author：entertainment 2025-10-02 22:56:17 - browse：3

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Medicare drug price negotiation’s day in court

WSS

Congressmen charge Covid hearing ‘could have been an email’

Time to name cancers by genetics, not organ of origin, expert says

NIH trials fail to test meaningful long Covid therapies, experts say

Naloxone nonprofit donates 200,000 doses after FDA approval

Naloxone nonprofit donates 200,000 doses after FDA approval

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

focus

explore

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare drug price negotiation’s day in court

Hepatitis C has a cure — but many Americans still lack access to it

Cybersecurity threat forces Lurie Children's to take systems offline

Medical leaders decry Supreme Court decision on affirmative action

Woodcock on FDA’s accelerated approval and her next chapter

Continuity nursing helped my family in our darkest PICU moments

New Ultima Genomics DNA sequencer can read genome for $100

Medicare proposal to cover medical devices draws a mixed reaction

Wegovy trial has doctors encouraged over new possibilities

focus

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

FDA drug safety: Singulair case shows systemic surveillance flaws

General Catalyst, Summa Health deal will turn on physician buy

Do digital therapeutics have a future in medicine?

New Ultima Genomics DNA sequencer can read genome for $100

Woodcock on FDA’s accelerated approval and her next chapter

hotspot

Wikipedia

focus

leisure time